Treatment of vitiligo with topical imiquimod
AB Bong,
H Gollnick,
MP Schön,
AB Bong
Department of Dermatology and Venereology, Otto-von-Guericke-University, Magdeburg, Germany.
Search for more papers by this authorH Gollnick
Department of Dermatology and Venereology, Otto-von-Guericke-University, Magdeburg, Germany.
Search for more papers by this authorCorresponding Author
MP Schön
Department of Dermatology and Venereology, Otto-von-Guericke-University, Magdeburg, Germany.
*Corresponding author, Rudolf Virchow Centre, DFG Research Centre for Experimental Biomedicine and Department of Dermatology and Venereology, Julius Maximilians University, Versbacher Str. 9, 97078 Würzburg, Germany, tel. + 49 931 201 48977; fax +49 931 201 48702; E-mail: [email protected]Search for more papers by this authorAB Bong,
H Gollnick,
MP Schön,
AB Bong
Department of Dermatology and Venereology, Otto-von-Guericke-University, Magdeburg, Germany.
Search for more papers by this authorH Gollnick
Department of Dermatology and Venereology, Otto-von-Guericke-University, Magdeburg, Germany.
Search for more papers by this authorCorresponding Author
MP Schön
Department of Dermatology and Venereology, Otto-von-Guericke-University, Magdeburg, Germany.
*Corresponding author, Rudolf Virchow Centre, DFG Research Centre for Experimental Biomedicine and Department of Dermatology and Venereology, Julius Maximilians University, Versbacher Str. 9, 97078 Würzburg, Germany, tel. + 49 931 201 48977; fax +49 931 201 48702; E-mail: [email protected]Search for more papers by this author
References
- 1 Kemp EH, Waterman EA, Weetman AP. Autoimmune aspects of vitiligo. Autoimmunity 2001; 34: 65–77.
- 2 Lang KS, Caroli CC, Muhm A, Wernet D, Moris A, Schittek B, Knauss-Scherwitz E, Stevanovic S, Rammensee HG, Garbe C. HLA-A2 restricted, melanocyte-specific CD8+ T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against Melan-A/MART1. J Invest Dermatol 2001; 116: 891–897.
- 3 Shaffrali F, Gawkrodger D. Management of vitiligo. Clin Exp Dermatol 2000; 25: 575–579.
- 4 Cotellessa C, Peris K, Caracciolo E, Mordenti C, Chimenti S. The use of topical diphenylcyclopropenone for the treatment of extensive alopecia areata. J Am Acad Dermatol 2001; 44: 73–76.
- 5 Marks R, Gebauer K, Shumack S, Amies M, Bryden J, Fox TL, Owens ML. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose–response trial. J Am Acad Dermatol 2001; 44: 807–813.
- 6 Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999; 41: 1002–1007.
- 7 Stockfleth E, Meyer T, Benninghoff B, Christophers E. Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases. Br J Dermatol 2001; 144: 1050–1053.
- 8 Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3: 196–200.
- 9 Schön M, Bong AB, Drewniok C, Herz J, Geilen CC, Reifenberger J, Benninghoff B, Slade HB, Gollnick H, Schön MP. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003; 95: 1138–1149.
- 10 Gollnick H, Barasso R, Jappe U, Ward K, Eul A, Carey-Yard M, Milde K. Safety and efficacy of imiquimod 5% cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day. Int J STD AIDS 2001; 12: 22–28.
Citing Literature
